IPO - Kairos Pharma, LTD.

Form Type: S-1

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000149315225004041

Filing Summary: Kairos Pharma, Ltd. is filing a Form S-1 registration statement with the SEC to offer up to 6,425,000 shares of common stock, consisting of shares underlying pre-funded warrants, common warrants, and placement agent warrants. The offering includes 2,500,000 shares underlying pre-funded warrants, 3,750,000 shares underlying common warrants issued in a PIPE Offering, and 175,000 shares underlying placement agent warrants. The company will not receive proceeds from the resale of these shares but may receive up to approximately $5.5 million from the exercise of the warrants. Proceeds from any warrant exercise are intended to fund clinical trials, potential acquisitions, and general corporate purposes. The company is classified as an emerging growth company and will utilize reduced reporting requirements. Their common stock is listed on NYSE American under the symbol 'KAPA,' with a last reported sale price of $1.53 per share on January 27, 2025. The registration is intended for delayed or continuous offering and the final effective date will be determined by the SEC. As such, investments in their securities carry a high degree of risk, which is discussed in the risk factors section of the prospectus.

Document Link: View Document